JP5599791B2 - ５−アルキニル−ピリミジン - Google Patents
５−アルキニル−ピリミジン Download PDFInfo
- Publication number
- JP5599791B2 JP5599791B2 JP2011520491A JP2011520491A JP5599791B2 JP 5599791 B2 JP5599791 B2 JP 5599791B2 JP 2011520491 A JP2011520491 A JP 2011520491A JP 2011520491 A JP2011520491 A JP 2011520491A JP 5599791 B2 JP5599791 B2 JP 5599791B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- amino
- pyrimidin
- methyl
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CBFWLCLJCZQUSF-UHFFFAOYSA-N C#Cc1cc(O)cnc1 Chemical compound C#Cc1cc(O)cnc1 CBFWLCLJCZQUSF-UHFFFAOYSA-N 0.000 description 1
- LOZKDFHJCRBAHN-UHFFFAOYSA-N C#Cc1cc(cn[nH]2)c2nc1 Chemical compound C#Cc1cc(cn[nH]2)c2nc1 LOZKDFHJCRBAHN-UHFFFAOYSA-N 0.000 description 1
- ZVGIVKMNLUTRPN-UHFFFAOYSA-N C#Cc1ccc(N)nc1 Chemical compound C#Cc1ccc(N)nc1 ZVGIVKMNLUTRPN-UHFFFAOYSA-N 0.000 description 1
- HZUKXEJXHASAII-UHFFFAOYSA-N CC(C)(C)OC(NC(CC1)CCN1c1nc(N)nc(C)c1C#Cc1ccc(N)nc1)=O Chemical compound CC(C)(C)OC(NC(CC1)CCN1c1nc(N)nc(C)c1C#Cc1ccc(N)nc1)=O HZUKXEJXHASAII-UHFFFAOYSA-N 0.000 description 1
- NZIBILSAWPIUGD-UHFFFAOYSA-N CCc(nc(N)nc1-c(ccc(C(O)=O)c2)c2F)c1C#Cc1ccc(N)nc1 Chemical compound CCc(nc(N)nc1-c(ccc(C(O)=O)c2)c2F)c1C#Cc1ccc(N)nc1 NZIBILSAWPIUGD-UHFFFAOYSA-N 0.000 description 1
- WXEVECTYHQGSJG-UHFFFAOYSA-N CCc(nc(N)nc1Cl)c1C#Cc1ccc(NC)nc1 Chemical compound CCc(nc(N)nc1Cl)c1C#Cc1ccc(NC)nc1 WXEVECTYHQGSJG-UHFFFAOYSA-N 0.000 description 1
- DODHDCCCJZINLU-UHFFFAOYSA-N CNc(nc1)ccc1C#[Si+](C)(C)C Chemical compound CNc(nc1)ccc1C#[Si+](C)(C)C DODHDCCCJZINLU-UHFFFAOYSA-N 0.000 description 1
- IUOSYBZGBGHMHM-UHFFFAOYSA-N CS(c(nc1-c2cccc(C(F)(F)F)c2)nc(N)c1C#Cc1ccc(N)nc1)(=O)=O Chemical compound CS(c(nc1-c2cccc(C(F)(F)F)c2)nc(N)c1C#Cc1ccc(N)nc1)(=O)=O IUOSYBZGBGHMHM-UHFFFAOYSA-N 0.000 description 1
- OBNMXSREGDGMPS-UHFFFAOYSA-N CSc(nc1-c2cccc(C(F)(F)F)c2)nc(N)c1I Chemical compound CSc(nc1-c2cccc(C(F)(F)F)c2)nc(N)c1I OBNMXSREGDGMPS-UHFFFAOYSA-N 0.000 description 1
- YEYXQXPLEYPNCK-UHFFFAOYSA-N Cc(nc(N)nc1-c(cc2)ccc2S(C)=O)c1C#C Chemical compound Cc(nc(N)nc1-c(cc2)ccc2S(C)=O)c1C#C YEYXQXPLEYPNCK-UHFFFAOYSA-N 0.000 description 1
- OBYCYAKZJYVPNA-UHFFFAOYSA-N Cc(nc(N)nc1-c(cc2)ccc2S(C)=O)c1I Chemical compound Cc(nc(N)nc1-c(cc2)ccc2S(C)=O)c1I OBYCYAKZJYVPNA-UHFFFAOYSA-N 0.000 description 1
- ZDQKGKHAUAUIPS-UHFFFAOYSA-N Cc(nc(N)nc1-c(cc2C(O)=O)ccc2Cl)c1C#Cc1ccc(N)nc1 Chemical compound Cc(nc(N)nc1-c(cc2C(O)=O)ccc2Cl)c1C#Cc1ccc(N)nc1 ZDQKGKHAUAUIPS-UHFFFAOYSA-N 0.000 description 1
- PJWZOJBQRPVNRC-UHFFFAOYSA-N Cc(nc(N)nc1-c(cc2C(O)=O)ccc2F)c1C#Cc1ccc(N)nc1 Chemical compound Cc(nc(N)nc1-c(cc2C(O)=O)ccc2F)c1C#Cc1ccc(N)nc1 PJWZOJBQRPVNRC-UHFFFAOYSA-N 0.000 description 1
- CVHNJHCSMZXKSF-UHFFFAOYSA-N Cc(nc(N)nc1-c2cc(C#N)ccc2)c1I Chemical compound Cc(nc(N)nc1-c2cc(C#N)ccc2)c1I CVHNJHCSMZXKSF-UHFFFAOYSA-N 0.000 description 1
- REBNOVWHLMTEHD-UHFFFAOYSA-N Cc(nc(N)nc1-c2cc(C(F)(F)F)ccc2)c1I Chemical compound Cc(nc(N)nc1-c2cc(C(F)(F)F)ccc2)c1I REBNOVWHLMTEHD-UHFFFAOYSA-N 0.000 description 1
- UTKGDJULUXUWHW-UHFFFAOYSA-N Cc(nc(N)nc1Cl)c1C#Cc1cc(O)ccc1 Chemical compound Cc(nc(N)nc1Cl)c1C#Cc1cc(O)ccc1 UTKGDJULUXUWHW-UHFFFAOYSA-N 0.000 description 1
- FLBMQEHVRKOQTR-UHFFFAOYSA-N Cc1cc(-c2cccc(C#N)c2)nc(N)n1 Chemical compound Cc1cc(-c2cccc(C#N)c2)nc(N)n1 FLBMQEHVRKOQTR-UHFFFAOYSA-N 0.000 description 1
- RMJZHPDSXCBTBL-UHFFFAOYSA-N Nc1cc(-c2cc(C(F)(F)F)ccc2)nc(N)n1 Chemical compound Nc1cc(-c2cc(C(F)(F)F)ccc2)nc(N)n1 RMJZHPDSXCBTBL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Laminated Bodies (AREA)
- Application Of Or Painting With Fluid Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08161369.7 | 2008-07-29 | ||
| EP08161369 | 2008-07-29 | ||
| PCT/EP2009/059763 WO2010012740A1 (en) | 2008-07-29 | 2009-07-28 | 5-alkynyl-pyrimidines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011529468A JP2011529468A (ja) | 2011-12-08 |
| JP2011529468A5 JP2011529468A5 (OSRAM) | 2012-08-30 |
| JP5599791B2 true JP5599791B2 (ja) | 2014-10-01 |
Family
ID=40202900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011520491A Active JP5599791B2 (ja) | 2008-07-29 | 2009-07-28 | ５−アルキニル−ピリミジン |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8916548B2 (OSRAM) |
| EP (1) | EP2323992B1 (OSRAM) |
| JP (1) | JP5599791B2 (OSRAM) |
| KR (1) | KR20110041536A (OSRAM) |
| CN (1) | CN102112450A (OSRAM) |
| AR (1) | AR072845A1 (OSRAM) |
| AU (1) | AU2009275957A1 (OSRAM) |
| BR (1) | BRPI0916679A2 (OSRAM) |
| CA (1) | CA2731909A1 (OSRAM) |
| CL (1) | CL2011000195A1 (OSRAM) |
| CO (1) | CO6341617A2 (OSRAM) |
| DK (1) | DK2323992T3 (OSRAM) |
| EA (1) | EA201100255A1 (OSRAM) |
| EC (1) | ECSP11010786A (OSRAM) |
| ES (1) | ES2597903T3 (OSRAM) |
| HU (1) | HUE029837T2 (OSRAM) |
| IL (1) | IL210343A0 (OSRAM) |
| MA (1) | MA32505B1 (OSRAM) |
| MX (1) | MX2011000729A (OSRAM) |
| NZ (1) | NZ590558A (OSRAM) |
| PE (1) | PE20110196A1 (OSRAM) |
| PL (1) | PL2323992T3 (OSRAM) |
| TW (1) | TW201010984A (OSRAM) |
| UY (1) | UY32009A (OSRAM) |
| WO (1) | WO2010012740A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR072845A1 (es) | 2008-07-29 | 2010-09-22 | Boehringer Ingelheim Int | 5-alquil-pirimidinas y su uso en el tratamiento de enfermedades mediadas por la actividad de quinasas. |
| US8853420B2 (en) | 2008-07-29 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Compounds |
| AR076332A1 (es) | 2009-04-21 | 2011-06-01 | Boehringer Ingelheim Int | Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones. |
| UY33199A (es) * | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
| US8618111B2 (en) * | 2010-01-26 | 2013-12-31 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
| TW201245176A (en) * | 2011-01-26 | 2012-11-16 | Boehringer Ingelheim Int | New 5-alkynyl-pyridines |
| US8466162B2 (en) * | 2011-01-26 | 2013-06-18 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyridines |
| JP6016915B2 (ja) * | 2011-07-28 | 2016-10-26 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤として活性なアルキニル置換ピリミジニルピロール |
| UA110995C2 (uk) * | 2011-10-07 | 2016-03-10 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як модулятори метаботропного глутаматного рецептора |
| SI3080100T1 (sl) * | 2013-12-11 | 2023-04-28 | Celgene Quanticel Research, Inc. | Inhibitorji lizin specifične demetilaze-1 |
| WO2015168466A1 (en) | 2014-05-01 | 2015-11-05 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| JP6692350B2 (ja) * | 2014-09-05 | 2020-05-13 | セルジーン クオンティセル リサーチ，インク． | リジン特異的なデメチラーゼ−１の阻害剤 |
| CN104803921A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种苯取代嘧啶衍生物的制备方法 |
| CN104744376A (zh) * | 2015-03-14 | 2015-07-01 | 长沙深橙生物科技有限公司 | 一种2-异丙基嘧啶衍生物的制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3832570A1 (de) * | 1988-09-24 | 1990-03-29 | Hoechst Ag | 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte |
| JPH08504798A (ja) | 1992-12-18 | 1996-05-21 | ザ ウエルカム ファウンデーション リミテッド | 酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体 |
| US5622954A (en) | 1994-05-11 | 1997-04-22 | Fmc Corporation | 5[W(substituted aryl)alkenylene and alkynylene]-2,4-diaminopyrimidines as pesticides |
| BR0108611A (pt) * | 2000-02-25 | 2003-05-06 | Hoffmann La Roche | Moduladores de receptor de adenosina |
| JP5154728B2 (ja) * | 2000-07-24 | 2013-02-27 | クレニツキー・ファーマシューティカルズ，インコーポレイテッド | 神経栄養活性を有する置換５−アルキニルピリミジン |
| WO2005016245A2 (en) * | 2003-06-13 | 2005-02-24 | Zentaris Gmbh | Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof |
| JP2007517006A (ja) | 2003-12-24 | 2007-06-28 | アストラゼネカ アクチボラグ | Ｔｉｅ２（ｔｅｋ）活性のあるピリミジン |
| ES2873875T3 (es) * | 2004-05-13 | 2021-11-04 | Icos Corp | Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano |
| US7776869B2 (en) * | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| US20100048543A1 (en) | 2005-02-01 | 2010-02-25 | Astrazeneca Ab | Pyrimidine compounds having ties (tek) inhibitory activity |
| US20080146599A1 (en) | 2005-02-01 | 2008-06-19 | Astrazeneca Ab | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity |
| US20070135437A1 (en) | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
| JP4993205B2 (ja) | 2005-03-30 | 2012-08-08 | 塩野義製薬株式会社 | チロシンキナーゼ阻害作用を有するピリミジン誘導体 |
| WO2006103449A2 (en) | 2005-03-31 | 2006-10-05 | Astrazeneca Ab | Saminopyrimidine derivates with tie2 inhibiting activity |
| CN101282948A (zh) * | 2005-10-07 | 2008-10-08 | 埃克塞里艾克西斯公司 | N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途 |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US20090325957A1 (en) | 2006-08-24 | 2009-12-31 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| EA020749B1 (ru) | 2006-12-29 | 2015-01-30 | Тиботек Фармасьютикалз Лтд. | Вич-ингибирующие 5,6-замещенные пиримидины |
| EP2022785A1 (en) | 2007-06-20 | 2009-02-11 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as Tie2 kinase inhibitors |
| AR072845A1 (es) | 2008-07-29 | 2010-09-22 | Boehringer Ingelheim Int | 5-alquil-pirimidinas y su uso en el tratamiento de enfermedades mediadas por la actividad de quinasas. |
| UY33199A (es) | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
-
2009
- 2009-07-28 AR ARP090102873A patent/AR072845A1/es unknown
- 2009-07-28 JP JP2011520491A patent/JP5599791B2/ja active Active
- 2009-07-28 PL PL09781207T patent/PL2323992T3/pl unknown
- 2009-07-28 NZ NZ590558A patent/NZ590558A/xx not_active IP Right Cessation
- 2009-07-28 CA CA2731909A patent/CA2731909A1/en not_active Abandoned
- 2009-07-28 HU HUE09781207A patent/HUE029837T2/en unknown
- 2009-07-28 AU AU2009275957A patent/AU2009275957A1/en not_active Abandoned
- 2009-07-28 MX MX2011000729A patent/MX2011000729A/es unknown
- 2009-07-28 TW TW098125388A patent/TW201010984A/zh unknown
- 2009-07-28 WO PCT/EP2009/059763 patent/WO2010012740A1/en not_active Ceased
- 2009-07-28 CN CN2009801301499A patent/CN102112450A/zh active Pending
- 2009-07-28 PE PE2011000088A patent/PE20110196A1/es not_active Application Discontinuation
- 2009-07-28 EP EP09781207.7A patent/EP2323992B1/en active Active
- 2009-07-28 BR BRPI0916679A patent/BRPI0916679A2/pt not_active IP Right Cessation
- 2009-07-28 ES ES09781207.7T patent/ES2597903T3/es active Active
- 2009-07-28 DK DK09781207.7T patent/DK2323992T3/en active
- 2009-07-28 KR KR1020117003951A patent/KR20110041536A/ko not_active Withdrawn
- 2009-07-28 US US13/055,949 patent/US8916548B2/en active Active
- 2009-07-28 UY UY0001032009A patent/UY32009A/es not_active Application Discontinuation
- 2009-07-28 EA EA201100255A patent/EA201100255A1/ru unknown
-
2010
- 2010-12-29 IL IL210343A patent/IL210343A0/en unknown
-
2011
- 2011-01-26 MA MA33560A patent/MA32505B1/fr unknown
- 2011-01-27 CO CO11009242A patent/CO6341617A2/es not_active Application Discontinuation
- 2011-01-27 EC EC2011010786A patent/ECSP11010786A/es unknown
- 2011-01-28 CL CL2011000195A patent/CL2011000195A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2323992T3 (pl) | 2017-01-31 |
| US20110281838A1 (en) | 2011-11-17 |
| CL2011000195A1 (es) | 2011-07-08 |
| TW201010984A (en) | 2010-03-16 |
| PE20110196A1 (es) | 2011-04-03 |
| WO2010012740A1 (en) | 2010-02-04 |
| IL210343A0 (en) | 2011-03-31 |
| ECSP11010786A (es) | 2011-02-28 |
| HUE029837T2 (en) | 2017-04-28 |
| EA201100255A1 (ru) | 2011-08-30 |
| JP2011529468A (ja) | 2011-12-08 |
| DK2323992T3 (en) | 2016-10-31 |
| CA2731909A1 (en) | 2010-02-04 |
| CN102112450A (zh) | 2011-06-29 |
| CO6341617A2 (es) | 2011-11-21 |
| EP2323992B1 (en) | 2016-07-20 |
| KR20110041536A (ko) | 2011-04-21 |
| US8916548B2 (en) | 2014-12-23 |
| AU2009275957A1 (en) | 2010-02-04 |
| ES2597903T3 (es) | 2017-01-24 |
| MA32505B1 (fr) | 2011-07-03 |
| BRPI0916679A2 (pt) | 2015-11-17 |
| UY32009A (es) | 2010-02-26 |
| MX2011000729A (es) | 2011-03-15 |
| EP2323992A1 (en) | 2011-05-25 |
| AR072845A1 (es) | 2010-09-22 |
| NZ590558A (en) | 2012-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5599791B2 (ja) | ５−アルキニル−ピリミジン | |
| JP5746219B2 (ja) | ５−アルキニル−ピリミジン | |
| JP5622740B2 (ja) | 新規化合物 | |
| JP5153773B2 (ja) | フェニル置換ヘテロアリール誘導体及び抗癌剤としてのその使用 | |
| JP5551066B2 (ja) | 新規化合物 | |
| JP5579724B2 (ja) | ホスファチジルイノシトール−３−キナーゼ（ｐｉ−３キナーゼ）阻害剤としてのテトラ−アザ−複素環 | |
| JP5651110B2 (ja) | 新規化合物 | |
| JP2010529161A (ja) | インドリノン誘導体及び癌等の症状を治療する際のそれらの使用 | |
| JP2008542433A (ja) | ＣＤＫ−１インヒビターとしてのα−カルボリン | |
| JP5635592B2 (ja) | ５−アルキニル−ピリジン | |
| JP2011513471A (ja) | チアゾリル−ジヒドロ−インダゾール | |
| HK1154004A (en) | 5-alkynyl-pyrimidines | |
| KR20130030742A (ko) | 5―알키닐―피리미딘 및 키나제 저해제로서 그의 용도 | |
| HK1165197A (en) | 5-alkynyl-pyridines | |
| HK1150835A (en) | Thiazolyl-dihydro-indazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120710 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120710 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131015 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140115 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140207 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140723 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140813 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5599791 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |